Braskem (BAK) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- $1.62
- Estimate
- -$3.59
- Surprise
- +145.2%
- Score today
- 5.3/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Braskem (BAK) beat the -$3.59 estimate with adjusted EPS of $1.62 — a large 145.2% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates BAK Sell at 5.3/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's +145.2% surprise compares with a +2.2% four-quarter average. Next scheduled report: 2026-11-12.
What argues against it
- Target reached (-11.6% upside)
- Quality below floor (2.8 < 4.0)
- Negative risk/reward — downside exceeds upside
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $1.87
- Price target
- $2.15
- Stop
- $1.74
- Upside to target
- +15.0%
Risk check: RSI 74 — a level conventionally read as overbought; gains at these levels often lean on momentum; trading volume is running 1.9× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-10-14 — shown for context, not personalized investment advice.
BAK at TrendMatrix's latest read
Materials producers report against the commodity cycle — realized-price capture and volume, not the EPS line, are the tells in a quarter like this.
- Industry
- Chemicals
- Market cap
- $422.5M
- P/E (fwd)
- -1.7
- 52-week range
- $1.40–$5.39
- Off 52-week high
- 65.3%
- RSI (14)
- 74
- Volume vs avg
- 1.88×
- Score today
- 5.3/10